NCT02785952
Clinical Trial Information
Trial Number: NCT02785952 (ClinicalTrials.gov)
Disease Type:
- Lung, Mediastinal and Pleural Neoplasm - Non-Small Cell Lung Cancer
Trial Title:
A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)
Study ID:
S1400I
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02785952-D3 | There are three datasets for PMID 34264316 containing the results reported in JAMA Oncology (Gettinger et al., JAMA Oncology, 2021). This dataset, NCT02785952-D3, contains biomarker data (one row per patient per gene alteration). |
| NCT02785952-D2 | There are three datasets for PMID 34264316 containing the results reported in JAMA Oncology (Gettinger et al., JAMA Oncology, 2021). This toxicity dataset, NCT02785952-D2, contains event-level data (one row per patient per adverse event experienced on trial). |
| NCT02785952-D1 | There are three datasets for PMID 34264316 containing the results reported in JAMA Oncology (Gettinger et al., JAMA Oncology, 2021). This clinical dataset, NCT02785952-D1, contains patient-level data (one row per patient), including baseline, demographic, and treatment information. It also contains assessment data. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®